psilocybin
Pre-clinical- Indications
- Anxiety, Depression, Mental health disorders
Company intelligence / Profile preview
Unlimited Sciences has published the world’s largest longitudinal dataset on naturalistic psilocybin use. Their findings indicate that a single dose of psilocybin can produce lasting improvements in mental health and wellbeing outside of clinical settings. The organization also conducts studies on ayahuasca use among immigrants/refugees and on functional mushrooms for epilepsy. Results support broad therapeutic potential for psychedelics as alternative or complementary treatments to conventional medicine.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Unlimited Sciences.